Use of attribute driven incremental discretization and logic learning machine to build a prognostic classifier for neuroblastoma patients

BMC Bioinformatics

Volumn 15, Issue , 2014, Pages

  Cangelosi, Davide ^a   Muselli, Marco ^b   Parodi, Stefano ^b   Blengio, Fabiola ^a   Becherini, Pamela ^a   Versteeg, Rogier ^c   Conte, Massimo ^a   Varesio, Luigi ^a  

^a G GASLINI INSTITUTE   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APPLICATION PROGRAMS; COMPUTER CIRCUITS; DECISION SUPPORT SYSTEMS; DISEASES; FORECASTING; GENE EXPRESSION; LEARNING ALGORITHMS; LEARNING SYSTEMS; METADATA; PROBES; TUMORS;

CANCER CLASSIFICATION; CLINICAL DECISION SUPPORT; CONTINUOUS VARIABLES; GENE EXPRESSION DATA; GENE EXPRESSION PROFILES; GENE EXPRESSION SIGNATURES; INTERPRETABLE RULES; MICROARRAY GENE EXPRESSION DATA;

CLASSIFICATION (OF INFORMATION);

ALGORITHM; ARTICLE; ARTIFICIAL INTELLIGENCE; BIOLOGY; COMPUTER PROGRAM; EQUIPMENT; GENE EXPRESSION PROFILING; GENETICS; HUMAN; INFANT; LOGIC; METHODOLOGY; NEUROBLASTOMA; PROGNOSIS; SUPPORT VECTOR MACHINE;

ALGORITHMS; ARTIFICIAL INTELLIGENCE; COMPUTATIONAL BIOLOGY; GENE EXPRESSION PROFILING; HUMANS; INFANT; LOGIC; NEUROBLASTOMA; PROGNOSIS; SOFTWARE; SUPPORT VECTOR MACHINES;

EID: 84907224077     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-15-S5-S4     Document Type: Article

References (64)

1. Fardin P, Barla A, Mosci S, Rosasco L, Verri A, Versteeg R, Caron HN, Molenaar JJ, Ora I, Eva A, et al: A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients. Molecular Cancer 2010, 9:185.
2. Thiele CJ: Neuroblastoma. In Human Cell Culture. London: Kluwer Academic; Master JRW, Palsson B 1999:21-22.
3. Haupt R, Garaventa A, Gambini C, Parodi S, Cangemi G, Casale F, Viscardi E, Bianchi M, Prete A, Jenkner A, et al: Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry. J Clin Oncol 2010, 28:2331-2338.
4. Doroshow JH: Selecting systemic cancer therapy one patient at a time: is there a role for molecular profiling of individual patients with advanced solid tumors? J Clin Oncol 2010, 28:4869-4871.
5. Wei J, Greer B, Westermann F, Steinberg S, Son C, Chen Q, Whiteford C, Bilke S, Krasnoselsky A, Cenacchi N, et al: Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 2004, 64:6883-6891.
6. Schramm A, Schulte JH, Klein-Hitpass L, Havers W, Sieverts H, Berwanger B, Christiansen H, Warnat P, Brors B, Eils J, et al: Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 2005, 24:7902-7912.
7. Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, Nakagawa A, Hirata T, Kubo H, Goto T, Yamada S: Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 2005, 7:337-350.
8. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, Ernestus K, Konig R, Haas S, Eils R, et al: Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006, 24:5070-5078.
9. Fischer M, Oberthuer A, Brors B, Kahlert Y, Skowron M, Voth H, Warnat P, Ernestus K, Hero B, Berthold F: Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Clin Cancer Res 2006, 12:5118-5128.
10. Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, Swerts K, Bravo S, Scaruffi P, Tonini GP, et al: Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 2009, 10:663-671.
11. De Preter K, Vermeulen J, Brors B, Delattre O, Eggert A, Fischer M, Janoueix-Lerosey I, Lavarino C, Maris JM, Mora J, et al: Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature. Clin Cancer Res 2010, 16:1532-1541.
12. Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y, Asgharzadeh S, Seeger R, Scaruffi P, Tonini GP, et al: Prognostic Impact of Gene Expression-Based Classification for Neuroblastoma. J Clin Oncol 2010, 28:3506-3515.
13. Cornero A, Acquaviva M, Fardin P, Versteeg R, Schramm A, Eva A, Bosco MC, Blengio F, Barzaghi S, Varesio L: Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome. BMC Bioinformatics 2012, 13(Suppl 4):S13.
14. Fardin P, Barla A, Mosci S, Rosasco L, Verri A, Varesio L: The l1-l2 regularization framework unmasks the hypoxia signature hidden in the transcriptome of a set of heterogeneous neuroblastoma cell lines. BMC Genomics 2009, 10:474.
15. Cangelosi D, Blengio F, Versteeg R, Eggert A, Garaventa A, Gambini C, Conte M, Eva A, Muselli M, Varesio L: Logic Learning Machine creates explicit and stable rules stratifying neuroblastoma patients. BMC Bioinformatics 2013, 14(Suppl 7):S12.
16. Pietras A, Johnsson AS, Pahlman S: The HIF-2alpha-driven pseudo-hypoxic phenotype in tumor aggressiveness, differentiation, and vascularization. Curr Top Microbiol Immunol 2010, 345:1-20.
17. Semenza GL: Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 2009, 19:12-16.
18. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, et al: Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998, 394:485-490.
19. Lin Q, Yun Z: Impact of the hypoxic tumor microenvironment on the regulation of cancer stem cell characteristics. Cancer Biol Ther 2010, 9:949-956.
20. Lu X, Kang Y: Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010, 16:5928-5935.
21. Chan DA, Giaccia AJ: Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 2007, 26:333-339.
22. Harris AL: Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47.
23. Rankin EB, Giaccia AJ: The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008, 15:678-685.
24. Fardin P, Cornero A, Barla A, Mosci S, Acquaviva M, Rosasco L, Gambini C, Verri A, Varesio L: Identification of Multiple Hypoxia Signatures in Neuroblastoma Cell Lines by l(1)-l(2) Regularization and Data Reduction. Journal of Biomedicine and Biotechnology 2010.
25. Kotsiantis SB, Zaharakis ID, Pintelas PE: Machine learning: a review of classification and combining techniques. Artif Intell Rev 2006, 26:159-190.
26. Tan AC, Naiman DQ, Xu LF, Winslow RL, Geman D: Simple decision rules for classifying human cancers from gene expression profiles. Bioinformatics 2005, 21:3896-3904.
27. Fürnkranz J: Separate-and-conquer rule learning. Artificial Intelligence Review 1999, 13:3-54.
28. Muselli M, Ferrari E: Coupling Logical Analysis of Data and Shadow Clustering for Partially Defined Positive Boolean Function Reconstruction. IEEE Transactions on Knowledge and Data Engineering 2011, 23:37-50.
29. Muselli M, Liberati D: Binary rule generation via Hamming Clustering. IEEE Transactions on Knowledge and Data Engineering 2002, 14:1258-1268.
30. Boros E, Hammer P, Ibaraki T, Kogan A, Muchnik I: An implementation of logical analysis of data. IEEE Transactions on Knowledge and Data Engineering 2000, 12:292-306.
31. Muselli M, Costacurta M, Ruffino F: Evaluating switching neural networks through artificial and real gene expression data. Artif Intell Med 2009, 45:163-171.
32. Mangerini R, Romano P, Facchiano A, Damonte G, Muselli M, Rocco M, Boccardo F, Profumo A: The application of atmospheric pressure matrixassisted laser desorption/ionization to the analysis of long-term cryopreserved serum peptidome. Anal Biochem 2011, 417:174-181.
33. Muselli M: Switching Neural Networks: A New Connectionist Model for Classification. In WIRN/NAIS 2005 Volume 3931. Berlin: Springer-Verlag; Apolloni B, Marinaro M, Nicosia G, Tagliaferri R 2006:23-30.
34. Rocco CM, Muselli M: Approximate multi-state reliability expressions using a new machine learning technique. Reliability Engineering and System Safety 2005, 89:261-270.
35. Zambrano O, Rocco CM, Muselli M: Estimating female labor force participation through statistical and machine learning methods: A comparison. In Computational Intelligence in Economics and Finance Volume Berlin: Springer-Verlag; Shu-Heng C, Paul P W, Tzu-Wen K 2007:93-106.
36. Rocco CM, Muselli M: Machine learning models for bulk electric system well-being assessment. 12th Conference of the Spanish Association for Artificial Intelligence CAEPIA; 2007.
37. Paoli G, Muselli M, Bellazzi R, Corvo R, Liberati D, Foppiano F: Hamming clustering techniques for the identification of prognostic indices in patients with advanced head and neck cancer treated with radiation therapy. Med Biol Eng Comput 2000, 38:483-486.
38. Ferro P, Forlani A, Muselli M, Pfeffer U: Alternative splicing of the human estrogen receptor alpha primary transcript: mechanisms of exon skipping. Int J Mol Med 2003, 12:355-363.
39. Ferrari E, Muselli M: Maximizing pattern separation in discretizing continuous features for classification purposes. The 2010 International Joint Conference on Neural Networks (IJCNN) 2010, 2010:1-8, 18 July.
40. Rulex software suite. [http://www.impara-ai.com].
41. Boedigheimer MJ, Wolfinger RD, Bass MB, Bushel PR, Chou JW, Cooper MF, et al: Sources of variation in baseline gene expression levels from toxicogenomics study control animals across multiple laboratories. BMC Genomics 2008, 9:285.
42. Kohavi R, Sahami M: Error-Based and Entropy-Based Discretization of Continuous Features. Procedings of the Second International Conference on Knowledge Discovery and Data Mining AAAI Press; 1996, 114-119.
43. Tay FEH, Shen L: A Modified Chi2 Algorithm for Discretization. IEEE Transactions on Knowledge and Data Engineering 2002, 14:666-670.
44. Perkins NJ, Schisterman EF: The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006, 163:670-675.
45. Quinlan JR: C4.5: programs for machine learning Morgan Kaufmann Publishers Inc; 1993.
46. Chang C, Lin C: LIBSVM: A library for support vector machines. ACM Transactions on Intelligent Systems and Technology 2011, 2:1-27.
47. Tibshirani RF, Hastie TF, Narasimhan BF, Chu G: Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002, 99:6567-6572.
48. Blagus RF, Lusa L: Class prediction for high-dimensional class-imbalanced data. BMC Bioinformatics 2010, 11:523.
49. Takemura AF, Shimizu AF, Hamamoto K: A cost-sensitive extension of AdaBoost with markov random field priors for automated segmentation of breast tumors in ultrasonic images. Int J Comput Assist Radiol Surg 2010, 5:537-547.
50. Vidrighin CF, Potolea R: ProICET: a cost-sensitive system for prostate cancer data. Health informatics journal 2008, 14:297-307.
51. Sun TF, Zhang RF, Wang JF, Li XF, Guo X: Computer-aided diagnosis for early-stage lung cancer based on longitudinal and balanced data. PLoS ONE 2013, 8:e63559.
52. Doyle S, Monaco JF, Feldman MF, Tomaszewski JF, Madabhushi A: An active learning based classification strategy for the minority class problem: application to histopathology annotation. BMC Bioinformatics 2011, 12:424.
53. Teramoto R: Balanced gradient boosting from imbalanced data for clinical outcome prediction. Stat Appl Genet Mol Biol 2009, 8:1544-6115, (Electronic).
54. Maxwell P, Pugh C, Ratcliffe P: Activation of the HIF pathway in cancer. Current Opinion in Genetics & Development 2001, 11:293-299.
55. Oberthuer A, Warnat P, Kahlert Y, Westermann F, Spitz R, Brors B, Hero B, Eils R, Schwab M, Berthold F, et al: Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease. Cancer Letters 2007, 250:250-267.
56. Schramm A, Mierswa I, Kaderali L, Morik K, Eggert A, Schulte JH: Reanalysis of neuroblastoma expression profiling data using improved methodology and extended follow-up increases validity of outcome prediction. Cancer Lett 2009, 282:55-62.
57. Mccall MN, Almudevar A: Affymetrix GeneChip microarray preprocessing for multivariate analyses. Briefings in Bioinformatics 2012, 13:536-546.
58. Upton GJG, Harrison AP: Motif effects in Affymetrix GeneChips seriously affect probe intensities. Nucleic Acids Res 2012, 40:9705-9716.
59. Brown JM, William WR: Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004, 4:437-447.
60. Johnson WE, Li CF, Rabinovic A: Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007, 8:118-127.
61. Luo JF, Schumacher MF, Scherer AF, Sanoudou DF, Megherbi DF, Davison TF, Shi TF, Tong WF, Shi LF, Hong HF, et al: A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data. Pharmacogenomics J 2010, 10:278-291.
62. Huang S, Laoukili J, Epping MT, Koster J, Holzel M, Westerman BA, Nijkamp W, Hata A, Asgharzadeh S, Seeger RC, et al: ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell 2009, 15:328-340.
63. Ohtaki M, Otani K, Hiyama K, Kamei N, Satoh K, Hiyama E: A robust method for estimating gene expression states using Affymetrix microarray probe level data. BMC Bioinformatics 2010, 11:183.
64. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD: The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 2012, 28:882-883.